Chinese monogenic diabetes registry
Official title: China Monogenic Diabetes Registry
Run by Tianjin Medical University General Hospital · NCT07492004 · Data updated 2026-11-12
This project will test whether an online and mobile registry can find and genetically confirm people in China with monogenic forms of diabetes, including neonatal diabetes and MODY.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Tianjin Medical University General Hospital Academic / other |
| Locations | 1 site (Tianjin) |
| Status | Recruiting |
| Started | February 28, 2021 |
| Main results expected | July 31, 2030 |
| Study ends | July 31, 2030 |
| Registry record updated | March 25, 2026 |
| Trial ID | NCT07492004 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people diagnosed with diabetes before age 25, or before age 35 with at least one first‑degree relative diagnosed before 40, who were relatively lean at diagnosis (BMI ≤28 kg/m²) and are GAD‑antibody negative.
✕Probably not a fit
People with secondary diabetes, active malignancy or a history of cancer within the past five years, or those with typical late‑onset obesity‑related type 2 diabetes are unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants enroll through a mobile app or web platform and provide clinical information and consent for molecular genetic testing. The study performs targeted genetic sequencing and broader omics analyses on collected samples to characterize pathogenic variants and their distribution in the Chinese population. Data and specimens are stored in a centralized database and biobank to support follow-up, family screening, and future research. The registry aggregates subjects from related monogenic diabetes cohorts (neonatal diabetes, MODY, maternally inherited diabetes and deafness) to build a large sample set.
Why it matters
Potential benefit: If successful, the registry could help more people obtain a genetic diagnosis that enables personalized treatment decisions and family screening.
How similar studies have gone: Similar national and regional monogenic diabetes registries and genetic screening programs have successfully identified pathogenic variants and changed patient management, so this approach has precedent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age 2. Body mass index (BMI) at diagnosis 28 kg/m² 3. Negative glutamic acid decarboxylase antibody (GAD-Ab) Exclusion Criteria: 1. Secondary diabetes 2. Active malignancy or history of malignant tumor within the past 5 years
Where it's running
-
Tianjin medical university general hospital
Tianjin, China Recruiting
Study contacts
- Study coordinator: Ming Liu
- Email: mingliu@tmu.edu.cn
- Phone: +86 022-27813550
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Identifying Monogenic Diabetes Misdiagnosed as Type 1
This study is trying to find out how often young people are wrongly diagnosed with type 1 diabetes when they actually have a rare form called monogenic diabetes, by testing their blood and looking for specific genetic changes.
-
Liraglutide for people with maturity-onset diabetes of the young (MODY)
This trial will try liraglutide in people with genetically confirmed MODY to see if it improves blood sugar, body weight, and gastrointestinal symptoms.
-
Dorzagliatin for glucokinase (GCK-MODY) diabetes
This trial will test whether dorzagliatin, a drug that activates glucokinase, can lower blood sugar in adults with GCK-MODY caused by an inactivating GCK mutation.
-
Personalized management for monogenic diabetes using genetic screening
This study is testing a new online platform that helps people with monogenic diabetes by using genetic screening to create personalized treatment plans for better blood sugar control.
-
Understanding beta cell disorders through genetic insights
This study is trying to learn more about beta cell problems, like diabetes, by looking at the genes of people with and without these issues to see if it can help find new treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.